NovoCure Ltd is an oncology company with a proprietary platform technology in the United States... Show more
A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with BLFS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then BLFS could also see price increases.
| Ticker / NAME | Correlation To NVCR | 1D Price Change % | ||
|---|---|---|---|---|
| NVCR | 100% | +2.53% | ||
| BLFS - NVCR | 39% Loosely correlated | N/A | ||
| ALGN - NVCR | 38% Loosely correlated | +1.19% | ||
| AZTA - NVCR | 38% Loosely correlated | +4.78% | ||
| TWST - NVCR | 37% Loosely correlated | +5.08% | ||
| A - NVCR | 35% Loosely correlated | +1.41% | ||
More | ||||
| Ticker / NAME | Correlation To NVCR | 1D Price Change % |
|---|---|---|
| NVCR | 100% | +2.53% |
| Medical/Nursing Services industry (139 stocks) | -3% Poorly correlated | +0.94% |
| Health Services industry (240 stocks) | -4% Poorly correlated | +0.89% |
a commercial-stage oncology company
Industry MedicalNursingServices
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NVCR declined for three days, in 311 of 351 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVCR as a result. In 64 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for NVCR turned negative on September 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
NVCR moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVCR crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for NVCR entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NVCR's RSI Oscillator exited the oversold zone, 27 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCR advanced for three days, in 209 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
NVCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. NVCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.453) is normal, around the industry mean (10.930). NVCR's P/E Ratio (1465.370) is considerably higher than the industry average of (100.178). Projected Growth (PEG Ratio) (40.950) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.